

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

**For the month of July 2020**

Commission File Number: **001-35165**

**BRAINSWAY LTD.**

(Translation of registrant's name into English)

**19 Hartum Street  
Bynet Building, 3rd Floor  
Har HaHotzvim  
Jerusalem, 9777518, Israel**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

EXHIBIT INDEX

**Exhibit**   **Title**

99.1   [BrainsWay to Report Second Quarter 2020 Financial Results and Operational Highlights on August 12, 2020](#)

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BRAINSWAY LTD.**

(Registrant)

Date: July 29, 2020

/s/ Christopher R. von Jako, Ph.D.

Christopher R. von Jako, Ph.D.  
President and Chief Executive Officer



## **BrainsWay to Report Second Quarter 2020 Financial Results and Operational Highlights on August 12, 2020**

**CRESSKILL, N.J. and JERUSALEM, Israel, July 29, 2020 (GLOBE NEWSWIRE)** – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its second quarter 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

### **Conference Call Dial-In & Webcast Information:**

Date:	Wednesday, August 12, 2020
Time:	8:30 AM Eastern Time
United States:	877-407-3982
Israel:	1 809 406 247
International:	201-493-6780
Conference ID:	13706952
Webcast:	<a href="http://public.viavid.com/index.php?id=140751">http://public.viavid.com/index.php?id=140751</a>

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, <https://investors.brainsway.com/financial-calendar>. Please access the Company’s website at least 10 minutes ahead of the conference call to register.

### **About BrainsWay**

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 for MDD and in 2018 for OCD. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

### **Forward Looking Statements**

Any forward-looking statements are subject to risks and uncertainties such as those described in BrainsWay’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.



**BrainsWay**

**Contacts:**

BrainsWay

Judy Huber

SVP and Chief Financial Officer

[Judy.huber@brainsway.com](mailto:Judy.huber@brainsway.com)

**Investors:**

Bob Yedid

LifeSci Advisors

646-597-6989

[Bob@LifeSciAdvisors.com](mailto:Bob@LifeSciAdvisors.com)